Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.

Yamaoka M, Hara T, Kusaka M.

Clin Cancer Res. 2010 Sep 1;16(17):4319-24. doi: 10.1158/1078-0432.CCR-10-0255. Epub 2010 Jul 20. Review.

2.

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP.

Cancer Res. 2011 Oct 15;71(20):6503-13. doi: 10.1158/0008-5472.CAN-11-0532. Epub 2011 Aug 25.

3.

Changing therapeutic paradigms in castrate-resistant prostate cancer.

Zivi A, Massard C, De-Bono J.

Clin Genitourin Cancer. 2010 Dec 1;8(1):17-22. doi: 10.3816/CGC.2010.n.003. Review.

PMID:
21208851
4.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
5.

Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

Cai C, Balk SP.

Endocr Relat Cancer. 2011 Aug 30;18(5):R175-82. doi: 10.1530/ERC-10-0339. Print 2011 Oct. Review.

6.

Targeting extra-gonadal androgens in castration-resistant prostate cancer.

Grist E, de Bono JS, Attard G.

J Steroid Biochem Mol Biol. 2015 Jan;145:157-63. doi: 10.1016/j.jsbmb.2014.09.006. Epub 2014 Sep 22. Review.

PMID:
25251387
7.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
9.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

10.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

11.

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB.

Clin Cancer Res. 2011 Sep 15;17(18):5913-25. doi: 10.1158/1078-0432.CCR-11-0728. Epub 2011 Aug 1.

12.

Abiraterone in prostate cancer: a new angle to an old problem.

Stein MN, Goodin S, Dipaola RS.

Clin Cancer Res. 2012 Apr 1;18(7):1848-54. doi: 10.1158/1078-0432.CCR-11-1805. Epub 2012 Mar 26. Review.

13.

Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.

Nandha R.

J Postgrad Med. 2012 Jul-Sep;58(3):203-6. Review.

14.

[New inhibitors of adrenal androgen synthesis enzymes].

Mizokami A.

Nihon Rinsho. 2014 Dec;72(12):2158-63. Japanese.

PMID:
25518351
15.

CYP17 inhibitors for prostate cancer therapy.

Vasaitis TS, Bruno RD, Njar VC.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):23-31. doi: 10.1016/j.jsbmb.2010.11.005. Epub 2010 Nov 17. Review.

16.

Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.

Mellado B, Marin Aguilera M, Pereira MV.

Arch Esp Urol. 2013 Jun;66(5):453-62. Review.

PMID:
23793763
17.

Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.

Eichholz A, Ferraldeschi R, Attard G, de Bono JS.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):68-75. doi: 10.1016/j.mce.2011.09.038. Epub 2011 Oct 1. Review.

PMID:
21986558
18.

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC.

Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.

19.

Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.

[No authors listed]

Med Lett Drugs Ther. 2011 Aug 25;53(1370):63-4. Review. No abstract available.

PMID:
21836546
20.

Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.

Kim W, Ryan CJ.

Curr Treat Options Oncol. 2012 Jun;13(2):189-200. doi: 10.1007/s11864-012-0188-2. Review.

PMID:
22539224

Supplemental Content

Support Center